These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33219119)

  • 1. Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.
    Apostolopoulou M; Gordillo R; Gancheva S; Strassburger K; Herder C; Esposito I; Schlensak M; Scherer PE; Roden M
    BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33219119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis.
    Apostolopoulou M; Gordillo R; Koliaki C; Gancheva S; Jelenik T; De Filippo E; Herder C; Markgraf D; Jankowiak F; Esposito I; Schlensak M; Scherer PE; Roden M
    Diabetes Care; 2018 Jun; 41(6):1235-1243. PubMed ID: 29602794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions.
    de la Monte SM; Tong M; Nguyen V; Setshedi M; Longato L; Wands JR
    J Alzheimers Dis; 2010; 21(3):967-84. PubMed ID: 20693650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
    Matsuzaka T; Kuba M; Koyasu S; Yamamoto Y; Motomura K; Arulmozhiraja S; Ohno H; Sharma R; Shimura T; Okajima Y; Han SI; Aita Y; Mizunoe Y; Osaki Y; Iwasaki H; Yatoh S; Suzuki H; Sone H; Takeuchi Y; Yahagi N; Miyamoto T; Sekiya M; Nakagawa Y; Ema M; Takahashi S; Tokiwa H; Shimano H
    Hepatology; 2020 May; 71(5):1609-1625. PubMed ID: 31529722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
    Yu XD; Wang JW
    Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.
    Bergman BC; Brozinick JT; Strauss A; Bacon S; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Perreault L
    Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E398-408. PubMed ID: 26126684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease.
    Ferreira DM; Castro RE; Machado MV; Evangelista T; Silvestre A; Costa A; Coutinho J; Carepa F; Cortez-Pinto H; Rodrigues CM
    Diabetologia; 2011 Jul; 54(7):1788-98. PubMed ID: 21455726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
    Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
    BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR
    Thompson D; Mahmood S; Morrice N; Kamli-Salino S; Dekeryte R; Hoffmann PA; Doherty MK; Whitfield PD; Delibegović M; Mody N
    Sci Rep; 2023 Mar; 13(1):3937. PubMed ID: 36894641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
    Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
    Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.
    Lyn-Cook LE; Lawton M; Tong M; Silbermann E; Longato L; Jiao P; Mark P; Wands JR; Xu H; de la Monte SM
    J Alzheimers Dis; 2009; 16(4):715-29. PubMed ID: 19387108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.